摘要
目的:评估安罗替尼三线治疗广泛期小细胞肺癌的疗效。方法:选取2019年10月至2020年10月我院急诊科收治的30例广泛期SCLC患者,随机分为治疗组(安罗替尼治疗15例)和观察组(不接受治疗15例),评估安罗替尼三线治疗小细胞肺癌的无进展生存期,肿瘤标志物,生存质量和不良反应。结果:治疗组中位PFS为3.0个月,95%置信区间(confidence interval,CI)为2.4~3.6个月,观察组中位PFS为1.0个月,95%CI为0.9~1.1个月,两组数据比较有统计学意义(P<0.05)。治疗组治疗前后NSE值分别为(89.93±24.54)ng/mL和(45.34±32.27)ng/mL,治疗前后相比有统计学意义(P<0.05);观察组治疗前后NSE值分别为(73.78±53.24)ng/mL和(86.72±70.40)ng/mL,治疗前后相比无统计学意义(P>0.05)。治疗组治疗前后PS评分分别为1.20±0.68和1.40±0.51,治疗前后相比无统计学意义(P>0.05);观察组治疗前后PS评分分别为1.13±0.52和1.53±0.64,治疗前后相比无统计学意义(P>0.05)。治疗组常见不良反应为高血压、肝功能损害、胃肠道反应及乏力;观察组常见不良反应为骨髓抑制、胃肠道反应、乏力及皮疹。治疗组与观察组不良反应发生率分别为53.3%和60.0%,差异相比无统计学意义(P>0.05)。结论:安罗替尼用于三线治疗广泛期SCLC疗效明确,可延长患者无进展生存期,不良反应可接受,安全性较高。
Objective:To evaluate the efficacy of third-line treatment with arotinib in patients with extensive small cell lung cancer.Methods:30 patients with extensive SCLC admitted to the emergency department in our hospital from October 2019 to October 2020 were randomly divided into the treatment group(15 cases treated with arotinib)and the observation group(15 cases without treatment).To evaluate the progression free survival(PFS),tumor markers,quality of life and adverse reactions.Results:The median PFS of the treatment group was 3.0 months,95%confidence interval(CI)was 2.4~3.6 months,the median PFS of the observation group was 1.0 months,95%confidence interval(CI)was 0.9~1.1 months,the data of the two groups were statistically significant(P<0.05).The NSE of the treatment group before and after treatment were(89.93±24.54)ng/mL and(45.34±32.27)ng/mL,which was statistically significant before and after treatment(P<0.05).The NSE of the observation group before and after treatment were(73.78±53.24)ng/mL and(86.72±70.40)ng/mL,there was no statistical significance before and after treatment(P>0.05).PS score of treatment group before and after treatment was 1.20±0.68 and 1.40±0.51,there was no statistical significance before and after treatment(P>0.05).The PS score of the observation group before and after treatment was 1.13±0.52 and 1.53±0.64,there was no statistical significance before and after treatment(P>0.05).The common adverse reactions in the treatment group were hypertension,liver function damage,gastrointestinal reaction and fatigue.The common adverse reactions in the observation group were myelosuppression,gastrointestinal reaction,fatigue and rash.There was no significant difference between the two groups(P>0.05).Conclusion:The efficacy of enrotinib in the third line treatment of extensive SCLC is clear,which can prolong the progression free survival,with acceptable adverse reactions and high safety.
作者
施阳阳
李延文
SHI Yangyang;LI Yanwen(Emergency Department,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China)
出处
《现代肿瘤医学》
CAS
北大核心
2022年第4期618-621,共4页
Journal of Modern Oncology
关键词
安罗替尼
三线治疗
小细胞肺癌
anlotinib
third line treatment
small cell lung cancer
